

Comparing Adherence and Persistence Across 6 Chronic

Journal of Managed Care Pharmacy

15, 728-740

DOI: [10.18553/jmcp.2009.15.9.728](https://doi.org/10.18553/jmcp.2009.15.9.728)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Aspirin Adherence, Aspirin Dosage, and C-Reactive Protein in the First 3 Months After Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2010, 106, 1090-1094.	1.6	19
2	Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2010, 4, 1137.	1.8	16
3	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results. <i>Clinical Ophthalmology</i> , 2010, 4, 437.	1.8	3
4	Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. <i>Patient Preference and Adherence</i> , 2010, 4, 397.	1.8	46
5	First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. <i>Current Medical Research and Opinion</i> , 2010, 26, 2769-2777.	1.9	6
6	Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 313-326.	0.3	74
7	Variation in Antiepileptic Drug Adherence Among Older Patients with New-Onset Epilepsy. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1896-1904.	1.9	62
8	DPP-4 inhibitors: What may be the clinical differentiators?. <i>Diabetes Research and Clinical Practice</i> , 2010, 90, 131-140.	2.8	85
9	Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder. <i>Urology</i> , 2010, 76, 835-840.	1.0	46
10	Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. <i>Current Medical Research and Opinion</i> , 2010, 26, 2877-2887.	1.9	67
11	Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. <i>Current Medical Research and Opinion</i> , 2011, 27, 2335-2342.	1.9	14
12	Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. <i>Journal of Medical Economics</i> , 2011, 14, 75-86.	2.1	23
13	Persistence with Prostaglandin Agonist Use with and without Adjunctive Therapy for Glaucoma Patients. <i>Patient</i> , 2011, 4, 133-141.	2.7	4
14	Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. <i>Current Medical Research and Opinion</i> , 2011, 27, 961-968.	1.9	27
15	Assessment of reasons for overactive bladder treatment change. <i>Actas Urológicas Españolas (English)</i> Tj ETQq0 0,0 rgBT /Qverlock 10	0.2	14
16	The Patient-Centric Approach: The Importance of Setting Realistic Treatment Goals. <i>European Urology Supplements</i> , 2011, 10, 23-27.	0.1	3
17	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. <i>Atherosclerosis</i> , 2011, 217, 479-485.	0.8	26
18	Reasons for Bisphosphonate Exclusion in Patients Treated for Osteoporosis. <i>The Consultant Pharmacist</i> , 2011, 26, 325-331.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Descriptive Analysis of Mail Interventions with Physicians and Patients to Improve Adherence with Antihypertensive and Antidiabetic Medications in a Mixed-Model Managed Care Organization of Commercial and Medicare Members. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 355-366.	2.2	10
20	Adherence to Osteoporosis Treatment. <i>Canadian Pharmacists Journal</i> , 2011, 144, S21-S21.e1.	0.8	0
21	Medication Adherence, Comorbidities, and Health Risk Impacts on Workforce Absence and Job Performance. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 595-604.	1.7	14
22	Medication adherence: emerging use of technology. <i>Current Opinion in Cardiology</i> , 2011, 26, 279-287.	1.8	130
23	Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. <i>International Journal of Clinical Practice</i> , 2011, 65, 567-585.	1.7	228
25	Time-to-effect with darifenacin in overactive bladder: a pooled analysis. <i>International Urogynecology Journal</i> , 2011, 22, 1573-1580.	1.4	6
26	The use of erlotinib in daily practice: a study on adherence and patients' experiences. <i>BMC Cancer</i> , 2011, 11, 284.	2.6	21
27	Non-adherence to drug therapy and drug acquisition costs in a national population - a patient-based register study. <i>BMC Health Services Research</i> , 2011, 11, 326.	2.2	47
28	A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1073-1079.	1.9	30
29	Adherence to Treatment Guidelines and Therapeutic Regimens: A US Claims-Based Benchmark of a Commercial Population. <i>Population Health Management</i> , 2011, 14, 33-41.	1.7	15
30	The true cost of pharmacological disease prevention. <i>BMJ: British Medical Journal</i> , 2011, 342, d2175-d2175.	2.3	48
31	Importance of Including Early Nonadherence in Estimations of Medication Adherence. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1053-1060.	1.9	40
32	Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. <i>Patient Preference and Adherence</i> , 2011, 5, 441.	1.8	127
33	Perspectives on Adherence and Persistence With Oral Medications for Cancer Treatment. <i>Journal of Oncology Practice</i> , 2011, 7, 65-67.	2.5	40
34	Patient experience with darifenacin – results of a short-term community-based survey in managing overactive bladder. <i>Current Medical Research and Opinion</i> , 2011, 27, 431-437.	1.9	2
35	Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. <i>Journal of Medical Economics</i> , 2011, 14, 562-567.	2.1	40
36	Pharmacoeconomic aspects of poor adherence: can better adherence reduce healthcare costs?. <i>Journal of Medical Economics</i> , 2011, 14, 594-608.	2.1	33
37	The use of capecitabine in daily practice: a study on adherence and patients' experiences. <i>Patient Preference and Adherence</i> , 2012, 6, 741.	1.8	10

#	ARTICLE	IF	CITATIONS
38	Largest pharmacy conference in history to help pharmacists improve global health: Preview 2012 FIP centennial congress. <i>European Journal of Hospital Pharmacy</i> , 2012, 19, 414-415.	1.1	0
39	Humalog (lispro) for type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1541-1550.	3.1	10
40	Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 763-775.	2.8	14
41	Association of Race with Cumulative Exposure to Statins in Dialysis. <i>American Journal of Nephrology</i> , 2012, 36, 90-96.	3.1	7
42	Pharmacy Effect on Adherence to Antidiabetic Medications. <i>Medical Care</i> , 2012, 50, 685-691.	2.4	19
43	Topical prostaglandin fixed combinations in UK primary care: observational study using data from the health improvement network. <i>European Journal of Ophthalmology</i> , 2012, 22, 376-387.	1.3	1
44	Partner support, social-cognitive variables and their role in adherence to self-monitoring of blood glucose in type 2 diabetes. <i>European Diabetes Nursing</i> , 2012, 9, 81-86.	0.2	17
45	Disease Management and Medication Compliance. <i>Population Health Management</i> , 2012, 15, 20-28.	1.7	13
46	Does the presence of a pharmacist in primary care clinics improve diabetes medication adherence?. <i>BMC Health Services Research</i> , 2012, 12, 391.	2.2	16
47	Unintentional non-adherence to chronic prescription medications: How unintentional is it really?. <i>BMC Health Services Research</i> , 2012, 12, 98.	2.2	283
48	Medication Adherence Among Recipients with Chronic Diseases Enrolled in a State Medicaid Program. <i>Population Health Management</i> , 2012, 15, 253-260.	1.7	28
49	Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. <i>International Journal of Clinical Practice</i> , 2012, 66, 1042-1051.	1.7	17
50	Descriptive epidemiological study of the diagnosis of detrusor overactivity in urodynamic units in Spain. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 21-28.	0.2	0
51	Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients. <i>Advances in Therapy</i> , 2012, 29, 675-690.	2.9	110
52	Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age. <i>Drugs and Aging</i> , 2012, 29, 119-131.	2.7	33
53	Medication Adherence in the General Population. <i>PLoS ONE</i> , 2012, 7, e50537.	2.5	46
54	The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. <i>Patient Preference and Adherence</i> , 2012, 6, 323.	1.8	75
55	Overactive bladder, differential diagnosis, and clinical utility of fesoterodine. <i>International Journal of General Medicine</i> , 2012, 5, 943.	1.8	3

#	ARTICLE	IF	CITATIONS
56	Discontinuation of statins among patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 241-245.	4.0	11
57	Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1048-1056.	1.9	61
59	Adherence to Oral Antidiabetic Medications in the Pediatric Population With Type 2 Diabetes: A Retrospective Database Analysis. <i>Clinical Therapeutics</i> , 2012, 34, 712-719.	2.5	31
60	Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. <i>BJU International</i> , 2012, 110, 1767-1774.	2.5	286
61	GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. <i>Osteoporosis International</i> , 2012, 23, 223-231.	3.1	114
62	Adherence to osteoporosis medications amongst Singaporean patients. <i>Osteoporosis International</i> , 2012, 23, 1053-1060.	3.1	28
63	Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. <i>Osteoporosis International</i> , 2012, 23, 317-326.	3.1	224
64	Management of hyperglycemia in type 2 diabetes: evidence and uncertainty. <i>Cardiovascular Diabetology</i> , 2013, 12, 81.	6.8	10
65	Adherence with Medications Used to Treat Osteoporosis: Behavioral Insights. <i>Current Osteoporosis Reports</i> , 2013, 11, 21-29.	3.6	18
66	Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?. <i>Endocrine</i> , 2013, 44, 343-345.	2.3	20
67	Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism. <i>Patient</i> , 2013, 6, 213-224.	2.7	64
68	Medication adherence: a complex behavior of medication and illness beliefs. <i>Aging Health</i> , 2013, 9, 377-387.	0.3	10
69	New developments in the medical management of overactive bladder. <i>Maturitas</i> , 2013, 76, 225-229.	2.4	9
70	Marriage, bereavement and mortality: The role of health care utilization. <i>Journal of Health Economics</i> , 2013, 32, 33-50.	2.7	35
71	Proactive Pharmaceutical Care Interventions Improve Patients'™ Adherence to Lipid-Lowering Medication. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1448-1456.	1.9	32
72	Adherence to treatment in systemic lupus erythematosus patients. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 329-340.	3.3	140
73	How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus. <i>European Journal of Health Economics</i> , 2013, 14, 551-568.	2.8	20
74	Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. <i>Current Medical Research and Opinion</i> , 2013, 29, 1201-1209.	1.9	12

#	ARTICLE	IF	CITATIONS
75	Adherence, persistence and costâ€“consequence comparison of bimatoprost topical ocular formulations. <i>Current Medical Research and Opinion</i> , 2013, 29, 1187-1189.	1.9	5
76	Medication Adherence and Treatment Patterns for Hypogonadal Patients Treated with Topical Testosterone Therapy: A Retrospective Medical Claims Analysis. <i>Journal of Sexual Medicine</i> , 2013, 10, 1401-1409.	0.6	61
77	An adherence based costâ€“consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%. <i>Current Medical Research and Opinion</i> , 2013, 29, 1191-1200.	1.9	3
78	Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2013, 29, 1587-1597.	1.9	1
79	Association Between Consistent Omalizumab Treatment and Asthma Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 51-57.	3.8	28
80	Gender and racial disparities in adherence to statin therapy: A meta-analysis. <i>American Heart Journal</i> , 2013, 165, 665-678.e1.	2.7	201
81	Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall. <i>European Urology</i> , 2013, 64, 502-510.	1.9	22
82	Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder. <i>Clinical Therapeutics</i> , 2013, 35, 1744-1751.	2.5	100
83	Adherence Associated With Oral Medications in the Treatment of Spasticity. <i>PM and R</i> , 2013, 5, 747-756.	1.6	32
84	5-Years APAP adherence in OSA patients â€“ Do first impressions matter?. <i>Respiratory Medicine</i> , 2013, 107, 2046-2052.	2.9	27
85	Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy. <i>Obstetrics and Gynecology</i> , 2013, 121, 1291-1299.	2.4	115
86	Failure to refill essential prescription medications for asthma among pediatric Medicaid beneficiaries with persistent asthma. <i>Patient Preference and Adherence</i> , 2013, 7, 21.	1.8	13
87	Patient Characteristics Associated with Medication Adherence. <i>Clinical Medicine and Research</i> , 2013, 11, 54-65.	0.8	328
88	Patient self-reported adherence for the most common chronic medication therapy. <i>Scandinavian Journal of Public Health</i> , 2013, 41, 333-335.	2.3	8
89	Impact of Race on Cumulative Exposure to Antihypertensive Medications in Dialysis. <i>American Journal of Hypertension</i> , 2013, 26, 234-242.	2.0	5
90	New agents to treat lower urinary tract and pelvic floor disorders. <i>Canadian Urological Association Journal</i> , 2013, 7, 174.	0.6	2
91	Refill adherence and selfâ€“reported adverse drug reactions and subâ€“therapeutic effects: a populationâ€“based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1317-1325.	1.9	6
92	Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. <i>Journal of Medical Economics</i> , 2013, 16, 962-975.	2.1	17

#	ARTICLE	IF	CITATIONS
93	Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. <i>BJU International</i> , 2013, 112, 820-829.	2.5	10
94	AB1387â€¦Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: A patient perspective. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 717.3-717.	0.9	0
95	Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases. <i>Medical Care</i> , 2013, 51, S11-S21.	2.4	360
96	Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2013, 53, 520-529.	1.5	56
97	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular Health and Risk Management</i> , 2013, 9, 273.	2.3	7
98	Reducing Cardiovascular Medication Complexity in a German University Hospital: Effects of a Structured Pharmaceutical Management Intervention on Adherence. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 396-407.	2.2	38
99	Methodological Considerations in Estimating Adherence and Persistence for a Long-Acting Injectable Medication. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 756-766.	2.2	18
100	Geographic Variation in Medication Adherence in Commercial and Medicare Part D Populations. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 834-842.	2.2	34
101	Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. <i>Patient Preference and Adherence</i> , 2014, 8, 1653.	1.8	38
102	Adherence to Statins in Primary Prevention: Yearly Adherence Changes and Outcomes. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 51-57.	2.2	43
103	Latanoprost in the treatment of glaucoma. <i>Clinical Ophthalmology</i> , 2014, 8, 1967.	1.8	70
104	Association Between Dispensing Channel and Medication Adherence Among Medicare Beneficiaries Taking Medications to Treat Diabetes, High Blood Pressure, or High Blood Cholesterol. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 851-861.	2.2	17
105	Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1543.	2.2	149
106	The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. <i>Patient Preference and Adherence</i> , 2014, 8, 873.	1.8	48
107	Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. <i>Clinical Ophthalmology</i> , 2014, 8, 927.	1.8	13
108	Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2014, 8, 1097.	1.8	24
109	Evaluation of Increased Adherence and Cost Savings of an Employer Value-Based Benefits Program Targeting Generic Antihyperlipidemic and Antidiabetic Medications. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 141-150.	2.2	20
110	Duloxetine treatment adherence across mental health and chronic pain conditions. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 75.	1.9	6

#	ARTICLE	IF	CITATIONS
111	Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia. <i>American Journal of Men's Health</i> , 2014, 8, 267-272.	1.6	15
112	Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5125-5135.	3.2	33
113	Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. <i>Annals of Pharmacotherapy</i> , 2014, 48, 826-836.	1.9	2
114	Fesoterodine Prescription Fill Patterns and Evaluation of the YourWay Patient Support Plan for Patients With Overactive Bladder Symptoms and Physicians. <i>Postgraduate Medicine</i> , 2014, 126, 246-256.	2.0	4
115	Long-Term Treatment Patterns of Testosterone Replacement Medications. <i>Journal of Sexual Medicine</i> , 2014, 11, 2092-2099.	0.6	21
116	Effect of Multiple Pharmacy Use on Medication Adherence and Drug-Drug Interactions in Older Adults with Medicare Part D. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 244-252.	2.6	46
117	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2014, 9, 861-870.	2.0	27
118	Evaluation of Adherence to Ambulatory Liquid Oxygen Treatment: Are Commercialized Dual-Pressure Transducers Helpful?. <i>Respiratory Care</i> , 2014, 59, 1376-1380.	1.6	1
119	Effect of electronic prescribing with formulary decision support on medication tier, copayments, and adherence. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 79.	3.0	13
120	Revision and validation of Medication Adherence Reasons Scale (MAR-Scale). <i>Current Medical Research and Opinion</i> , 2014, 30, 211-221.	1.9	33
121	Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients. <i>Scandinavian Journal of Urology</i> , 2014, 48, 79-83.	1.0	23
122	Socioeconomic Status and Nonadherence to Antihypertensive Drugs: A Systematic Review and Meta-Analysis. <i>Value in Health</i> , 2014, 17, 288-296.	0.3	62
123	Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, e99-e112.	3.0	46
124	What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. <i>European Urology</i> , 2014, 65, 1211-1217.	1.9	193
125	A method for calculating adherence to polypharmacy from dispensing data records. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 192-201.	2.1	49
126	Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 120-127.	2.1	36
127	Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. <i>Osteoporosis International</i> , 2014, 25, 1807-12.	3.1	33
128	Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1535-1543.	2.3	25

#	ARTICLE	IF	CITATIONS
129	Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 335-346.	2.1	16
130	Impact of Health Literacy on Medication Adherence. <i>Annals of Pharmacotherapy</i> , 2014, 48, 741-751.	1.9	239
131	The impact of medication adherence on health outcomes for chronic metabolic diseases: A retrospective cohort study. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, e87-e98.	3.0	57
132	Dynamic Medication Adherence Modeling in Primary Prevention of Cardiovascular Disease: A Markov Microsimulation Methods Application. <i>Value in Health</i> , 2014, 17, 725-731.	0.3	8
133	Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1365-1374.	4.1	10
134	Adherence to warfarin treatment among patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2014, 103, 998-1005.	3.3	47
135	The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly. <i>Calcified Tissue International</i> , 2014, 94, 597-607.	3.1	48
136	Optimum Management of Overactive Bladder: Medication vs Botox [®] vs InterStim [®] vs Urgent [®] PC. <i>Urology Practice</i> , 2014, 1, 7-12.	0.5	6
137	Re: Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. <i>European Urology</i> , 2014, 65, 1220-1221.	1.9	0
138	Antihypertensive Drug Prescribing and Persistence Among New Elderly Users: Implications for Persistence Improvement Interventions. <i>Canadian Journal of Cardiology</i> , 2014, 30, 647-652.	1.7	21
139	Long-Term Adherence to Antimuscarinic Therapy in Everyday Practice: A Systematic Review. <i>Journal of Urology</i> , 2014, 191, 1003-1008.	0.4	137
141	Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?. <i>BMC Urology</i> , 2015, 15, 96.	1.4	63
142	Targeting Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in the United States and Peru. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 119-125.	2.1	25
143	Does increased adherence to medications change health care financial burdens for adults with diabetes?. <i>Journal of Diabetes</i> , 2015, 7, 872-880.	1.8	12
144	Adherence to fesoterodine in women with overactive bladder in routine clinical practice. <i>Actas Urológicas Españolas (English Edition)</i> , 2015, 39, 222-228.	0.2	1
145	Patients' and Spouses' Contribution Toward Adherence to Self-Care Behaviors in Type 2 Diabetes. <i>Research and Theory for Nursing Practice</i> , 2015, 29, 276-296.	0.4	8
146	Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24-weeks, randomised, open-label, multi-center trial. <i>International Journal of Clinical Practice</i> , 2015, 69, 1309-1315.	1.7	8
147	Does patient education increase antimuscarinic treatment persistence in overactive bladder syndrome?. <i>International Journal of Urological Nursing</i> , 2015, 9, 84-91.	0.2	0

#	ARTICLE	IF	CITATIONS
148	Effect of Physician Participation in a Multi-element Health Information and Data Exchange Program on Chronic Illness Medication Adherence. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 742-749.	1.5	2
149	Impact of Employer-Sponsored Onsite Pharmacy and Condition Management Programs on Medication Adherence. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 670-677.	0.9	4
150	Improving medication adherence: a framework for community pharmacy-based interventions. <i>Integrated Pharmacy Research & Practice</i> , 2015, 4, 175.	1.5	12
151	The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 678-687.	0.9	6
152	Health Care Adherence and Personalized Medicine. <i>SSRN Electronic Journal</i> , 2015, , .	0.4	0
153	Persistence and Compliance with Osteoporosis Therapies Among Women in a Commercially Insured Population in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 824-833.	0.9	38
154	Patient satisfaction with glaucoma therapy: reality or myth?. <i>Clinical Ophthalmology</i> , 2015, 9, 785.	1.8	57
155	Drug therapies in older adults (part 1). <i>Clinical Medicine</i> , 2015, 15, 47-53.	1.9	8
156	Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans. <i>Bone</i> , 2015, 78, 174-185.	2.9	14
157	Do patients initiate therapy? Primary non-adherence to statins and antidepressants in Iceland. <i>International Journal of Clinical Practice</i> , 2015, 69, 597-603.	1.7	17
158	Self-report measures of medication adherence behavior: recommendations on optimal use. <i>Translational Behavioral Medicine</i> , 2015, 5, 470-482.	2.4	524
159	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	1.5	430
160	Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction. <i>Current Medical Research and Opinion</i> , 2015, 31, 367-378.	1.9	3
161	Pharmacokinetics of Injectable, Long-Acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 59-66.	3.2	22
162	Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. <i>European Urology</i> , 2015, 68, 418-425.	1.9	147
163	The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. <i>Internal and Emergency Medicine</i> , 2015, 10, 119-122.	2.0	1
164	CPAP holiday: are we there yet?. <i>European Respiratory Journal</i> , 2015, 45, 574-575.	6.7	3
165	Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis. <i>Journal of Clinical Lipidology</i> , 2015, 9, 326-333.	1.5	2

#	ARTICLE	IF	CITATIONS
166	Medication adherence in the management of nocturia: challenges and solutions. <i>Patient Preference and Adherence</i> , 2015, 9, 77.	1.8	5
167	Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. <i>Patient Preference and Adherence</i> , 2015, 9, 121.	1.8	61
168	Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3913-3919.	3.2	147
169	Adherencia a fesoterodina en mujeres con vejiga hiperactiva en la práctica clínica diaria. <i>Actas Urológicas Españolas</i> , 2015, 39, 222-228.	0.7	1
170	Persistence and adherence to oral antidiabetics: a population-based cohort study. <i>Acta Diabetologica</i> , 2015, 52, 547-556.	2.5	37
171	The Potential Impact of Intelligent Systems for Mobile Health Self-Management Support: Monte Carlo Simulations of Text Message Support for Medication Adherence. <i>Annals of Behavioral Medicine</i> , 2015, 49, 84-94.	2.9	24
172	Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2015, 1, 12.	1.0	9
173	Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data. <i>Patient</i> , 2015, 8, 385-395.	2.7	18
174	Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis. <i>Current Medical Research and Opinion</i> , 2015, 31, 615-622.	1.9	4
175	Cultural factors related to adherence to imatinib in CML: A Mexican perspective. <i>Hematology</i> , 2015, 20, 72-76.	1.5	7
176	Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. <i>Osteoporosis International</i> , 2015, 26, 2401-2411.	3.1	80
177	Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. <i>Current Medical Research and Opinion</i> , 2015, 31, 1889-1895.	1.9	48
178	Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. <i>Archives of Osteoporosis</i> , 2015, 10, 231.	2.4	70
179	Initial Medication Adherence—Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report. <i>Value in Health</i> , 2015, 18, 690-699.	0.3	46
180	An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. <i>International Journal of Pharmaceutics</i> , 2015, 495, 579-587.	5.2	21
181	Adherence to oral migraine-preventive medications among patients with chronic migraine. <i>Cephalalgia</i> , 2015, 35, 478-488.	3.9	314
182	Healing Practices and Evidence-Based Medicine. , 2016, , 285-306.		0
183	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 685-698.	0.9	55

#	ARTICLE	IF	CITATIONS
184	Is the Currently Used Prescription Adjudication Date a Good Proxy for Calculating Medication Refill Adherence?. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1311-1317.	0.9	5
185	Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market. <i>Croatian Medical Journal</i> , 2016, 57, 582-590.	0.7	4
186	Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients. <i>International Journal of COPD</i> , 2017, Volume 12, 115-122.	2.3	25
187	Effect of Financial Stress and Positive Financial Behaviors on Cost-Related Nonadherence to Health Regimens Among Adults in a Community-Based Setting. <i>Preventing Chronic Disease</i> , 2016, 13, E46.	3.4	19
188	Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1509-1519.	1.8	44
189	Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1457-1471.	0.9	33
190	Persistence and compliance with medication management in the treatment of overactive bladder. <i>Investigative and Clinical Urology</i> , 2016, 57, 84.	2.0	60
191	Treatment Patterns Associated with ACR-Recommended Medications in the Management of Fibromyalgia in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 263-271.	0.9	28
192	Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine. <i>Patient Preference and Adherence</i> , 2016, 10, 391.	1.8	2
193	Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study. <i>Cardiovascular Therapeutics</i> , 2016, 34, 268-275.	2.5	7
194	Persistence with medication and overactive bladder: an ongoing challenge. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 475-481.	1.4	2
195	Relationship Between Medication Adherence and Distance to Dispensing Pharmacies and Prescribers Among an Urban Medicaid Population with Diabetes Mellitus. <i>Pharmacotherapy</i> , 2016, 36, 590-597.	2.6	22
196	Patients' experience and expectations of conservative management strategies, anti-muscarinics and treatment with intravesical onabotulinum toxin for overactive bladder – a qualitative interview study. <i>International Journal of Urological Nursing</i> , 2016, 10, 68-77.	0.2	3
197	Effects of breast cancer on chronic disease medication adherence among older women. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 898-907.	1.9	17
198	Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3759-3766.	3.2	22
199	How important it is for therapy adherence to be once a day?. <i>European Heart Journal Supplements</i> , 2016, 18, I7-I12.	0.1	15
200	Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 359-370.	1.4	17
201	What We Mean When We Talk About Adherence in Respiratory Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 802-812.	3.8	104

#	ARTICLE	IF	CITATIONS
202	Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications. <i>Ophthalmology and Therapy</i> , 2016, 5, 207-214.	2.3	4
203	Treatment discontinuation of oral hypoglycemic agents and healthcare utilization among patients with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1443-1451.	2.3	12
204	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. <i>Drug and Alcohol Dependence</i> , 2016, 166, 254-257.	3.2	34
205	Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder. <i>International Journal of Urology</i> , 2016, 23, 866-872.	1.0	4
206	Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study. <i>International Journal of Urology</i> , 2016, 23, 1009-1015.	1.0	14
207	Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates. <i>Advances in Therapy</i> , 2016, 33, 1374-1384.	2.9	31
208	Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders. <i>BMC Psychiatry</i> , 2016, 16, 444.	2.6	15
209	Persistence profile to nucleos(t)ide analogue treatment for patients with chronic hepatitis B. <i>European Journal of Hospital Pharmacy</i> , 2016, 23, 278-282.	1.1	0
210	Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome. <i>Quality of Life Research</i> , 2016, 25, 2021-2029.	3.1	13
211	Adherence to Oral Therapy for Urgency Urinary Incontinence. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2016, 22, 24-28.	1.1	8
212	A drug safety evaluation of mirabegron in the management of overactive bladder. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 689-696.	2.4	16
213	Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. <i>Current Medical Research and Opinion</i> , 2016, 32, 621-638.	1.9	58
214	Big data and ophthalmic research. <i>Survey of Ophthalmology</i> , 2016, 61, 443-465.	4.0	45
215	Predictors of medication adherence and persistence in Medicaid enrollees with developmental disabilities and type 2 diabetes. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 592-603.	3.0	19
216	The Contribution of Qualitative Research to Medication Adherence. <i>Handbooks in Health, Work, and Disability</i> , 2016, , 473-494.	0.0	5
217	Outcomes of different protocols of pelvic floor physical therapy and anti-cholinergics in women with wet overactive bladder: A 4-year follow-up. <i>Neurourology and Urodynamics</i> , 2017, 36, 755-758.	1.5	20
218	Adherence and Persistence Patterns in Medication Use Among Men With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. <i>American Journal of Men's Health</i> , 2017, 11, 164-169.	1.6	5
219	Persistence with mirabegron therapy for overactive bladder: A real life experience. <i>Neurourology and Urodynamics</i> , 2017, 36, 404-408.	1.5	30

#	ARTICLE	IF	CITATIONS
220	Adherence to therapies in cystic fibrosis: a targeted literature review. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 129-145.	2.5	70
221	Medical students'™ medication communication skills regarding drug prescription" a qualitative analysis of simulated physician-patient consultations. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 429-435.	1.9	14
222	Factors of adherence to treatment with tiroprium in employees. <i>Urological Science</i> , 2017, 28, 139-146.	0.6	0
223	Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. <i>European Urology</i> , 2017, 72, 389-399.	1.9	162
224	Better Persistence Rates with Mirabegron: Questions Raised. <i>European Urology</i> , 2017, 72, 400-401.	1.9	1
225	Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications. <i>Current Medical Research and Opinion</i> , 2017, 33, 1329-1336.	1.9	49
226	Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. <i>Neurourology and Urodynamics</i> , 2017, 36, 2123-2131.	1.5	21
227	Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. <i>BMC Urology</i> , 2017, 17, 30.	1.4	16
228	Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?. <i>International Urogynecology Journal</i> , 2017, 28, 409-415.	1.4	5
229	Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. <i>Aids</i> , 2017, 31, 1697-1707.	2.2	15
230	Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1321-1326.	3.3	36
231	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). <i>CNS Drugs</i> , 2017, 31, 421-432.	5.9	61
232	Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. <i>Journal of Medical Economics</i> , 2017, 20, 614-622.	2.1	10
233	Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. <i>American Journal of Ophthalmology</i> , 2017, 175, 137-147.	3.3	98
234	Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. <i>Journal of General Internal Medicine</i> , 2017, 32, 619-625.	2.6	63
235	Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. <i>Pharmacotherapy</i> , 2017, 37, 278-286.	2.6	5
236	Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. <i>International Journal of Urology</i> , 2017, 24, 757-764.	1.0	18
237	Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics) Tj ETQq1 1 0.784314 rgBT /Over International, 2017, 120, 611-622.	2.5	59

#	ARTICLE	IF	CITATIONS
238	Self-Reported Rates of Adherence to Aspirin Prescribed as an Antithrombotic Therapy Following Postoperative Total Joint Replacement. <i>Orthopaedic Nursing</i> , 2017, 36, 287-292.	0.4	5
239	One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. <i>Osteoporosis International</i> , 2017, 28, 2997-3004.	3.1	47
240	Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. <i>Current Medical Research and Opinion</i> , 2017, 33, 1783-1787.	1.9	25
241	Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial. <i>BMJ Open</i> , 2017, 7, e016551.	1.9	10
242	Using Individual Experiences With Experimental Medications to Predict Medication-Taking Behavior Postauthorization: A DIA Study Endpoints Workstream. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 404-415.	1.6	3
243	Urinary incontinence in women. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17042.	30.5	234
244	Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 129.	2.4	0
245	Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. <i>Cephalgia</i> , 2017, 37, 470-485.	3.9	256
246	The effect of instruction in analgesic use compared with neuromuscular exercise on knee-joint load in patients with knee osteoarthritis: a randomized, single-blind, controlled trial. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 470-480.	1.3	19
247	Medication Nonadherence: The Role of Cost, Community, and Individual Factors. <i>Health Services Research</i> , 2017, 52, 1511-1533.	2.0	12
248	Areas and factors associated with patients' dissatisfaction with glaucoma care. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 1849-1857.	1.8	4
249	Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 557-566.	1.8	23
250	Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation. <i>PLoS ONE</i> , 2017, 12, e0179546.	2.5	20
251	Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. <i>PLoS ONE</i> , 2017, 12, e0185946.	2.5	26
252	The development and feasibility of a personal health-optimization system for people with bipolar disorder. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 102.	3.0	13
253	Commentary on Hwang et al. <i>Journal of Ambulatory Care Management</i> , 2017, 40, 270-272.	1.1	0
254	Denosumab – a new medication in the treatment of postmenopausal osteoporosis. <i>Przegląd Menopauzalny</i> , 2017, 3, 75-78.	1.3	0
255	Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1093-1101.	1.8	14

#	ARTICLE	IF	CITATIONS
256	Drugs for the overactive bladder: are there differences in persistence and compliance?. <i>Translational Andrology and Urology</i> , 2017, 6, 597-601.	1.4	7
257	Treatment adherence in systemic lupus erythematosus and rheumatoid arthritis: time to focus on this important issue. <i>Rheumatology</i> , 2018, 57, 1507-1509.	1.9	17
258	Characterizing Treatment Utilization Patterns for Trigeminal Neuralgia in the United States. <i>Clinical Journal of Pain</i> , 2018, 34, 691-699.	1.9	19
259	Factors Associated with Patient Satisfaction in an Outpatient Glaucoma Population. <i>Seminars in Ophthalmology</i> , 2018, 33, 757-765.	1.6	6
260	Systematic Review of the Effect of Adherence to Statin Treatment on Critical Cardiovascular Events and Mortality in Primary Prevention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 200-215.	2.0	32
261	Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. <i>Sleep Medicine</i> , 2018, 44, 45-52.	1.6	8
262	Measuring medication adherence in older community-dwelling patients with multimorbidity. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 357-364.	1.9	34
263	Is it possible to cure the symptoms of the overactive bladder in women?. <i>International Urology and Nephrology</i> , 2018, 50, 433-439.	1.4	4
264	Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. <i>Endocrine</i> , 2018, 61, 23-27.	2.3	36
265	Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 205-213.	3.4	55
266	Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 487-497.	2.4	20
267	Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 148-152.	1.3	29
268	Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 26-32.	0.6	6
269	The effect of counseling on willingness to use a hypothetical medication and perceptions of medication safety. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 295-302.	3.0	3
270	Associations Among Depressive Symptoms, Wellness, Patient Involvement, Provider Cultural Competency, and Treatment Nonadherence: A Pilot Study Among Community Patients Seen at a University Medical Center. <i>Community Mental Health Journal</i> , 2018, 54, 138-148.	2.0	4
271	The NIH Science of Behavior Change Program: Transforming the science through a focus on mechanisms of change. <i>Behaviour Research and Therapy</i> , 2018, 101, 3-11.	3.1	303
273	Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 638-645.	4.4	6
274	In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review. <i>Heart Failure Reviews</i> , 2018, 23, 63-71.	3.9	25

#	ARTICLE	IF	CITATIONS
275	Medication Exposure in Highly Adherent Psychiatry Patients. <i>ACS Chemical Neuroscience</i> , 2018, 9, 555-562.	3.5	5
276	Expectations, concerns, and needs of patients who start drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia. <i>European Journal of General Practice</i> , 2018, 24, 19-25.	2.0	3
277	Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1040-1043.	4.4	101
278	Effectiveness of mailed letters to improve medication adherence among Medicare Advantage Plan participants with chronic conditions. <i>Patient Preference and Adherence</i> , 2018, Volume 13, 37-46.	1.8	3
279	Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. <i>BMJ Open</i> , 2018, 8, e021889.	1.9	81
280	Adherence to chronic medication in older populations: application of a common protocol among three European cohorts. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1975-1987.	1.8	68
281	Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e025102.	1.9	10
282	Impact of pharmacy services on initial clinical outcomes and medication adherence among veterans with uncontrolled diabetes. <i>BMC Health Services Research</i> , 2018, 18, 855.	2.2	15
283	Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. <i>PLoS Medicine</i> , 2018, 15, e1002655.	8.4	27
284	Detection of potential look-alike/sound-alike medication errors using Veterans Affairs administrative databases. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1460-1466.	1.0	7
285	Intravesical ATP instillation induces urinary frequency because of activation of bladder afferent nerves without inflammatory changes in mice: A promising model for overactive bladder. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 498-503.	2.1	7
286	Cardiovascular risk profile in individuals initiating treatment for overactive bladder – Challenges and learnings for comparative analysis using linked claims and electronic medical record databases. <i>PLoS ONE</i> , 2018, 13, e0205640.	2.5	5
287	The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1284-1294.	0.9	14
288	The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases. <i>Patient</i> , 2018, 11, 515-526.	2.7	5
289	A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. <i>BMC Urology</i> , 2018, 18, 76.	1.4	12
290	Psychosocial impact of diabetes. <i>Diabetic Medicine</i> , 2018, 35, 675-676.	2.3	1
291	Glaucoma therapy: preservative-free for all?. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 707-717.	1.8	42
292	Refill-Based Medication Use Quality Measures in Kidney Transplant Recipients: Examination of Proportion of Days Covered and Medication Possession Ratio. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 367-372.	0.9	3

#	ARTICLE	IF	CITATIONS
293	Posttransplant Medical Adherence: What Have We Learned and Can We Do Better?. Current Transplantation Reports, 2018, 5, 174-188.	2.0	30
294	Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014. Pharmacoepidemiology and Drug Safety, 2018, 27, 674-682.	1.9	53
295	Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 193-203.	2.2	12
296	Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs. Drugs - Real World Outcomes, 2018, 5, 169-179.	1.6	18
297	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Archives of Osteoporosis, 2018, 13, 85.	2.4	22
298	Anticholinergic Drugs for Overactive Bladder in Frail Older Patients: The Case Against. Drugs and Aging, 2018, 35, 773-776.	2.7	16
299	Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function. Current Urology Reports, 2018, 19, 86.	2.2	17
300	Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study. Arthritis Care and Research, 2019, 71, 903-913.	3.4	23
301	Moving from the Trial to the Real World: Improving Medication Adherence Using Insights of Implementation Science. Annual Review of Pharmacology and Toxicology, 2019, 59, 423-445.	9.4	17
302	Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O152-O161.	1.3	7
303	Ten-year Medicare budget impact of increased coverage for anti-obesity intervention. Journal of Medical Economics, 2019, 22, 1096-1104.	2.1	9
304	Statin Dosing Instructions, Medication Adherence, and Low-Density Lipoprotein Cholesterol: a Cohort Study of Incident Statin Users. Journal of General Internal Medicine, 2019, 34, 2559-2566.	2.6	6
305	New horizons in deprescribing for older people. Age and Ageing, 2019, 48, 768-775.	1.6	22
306	Combination therapy in overactive bladder—untapped research opportunities: A systematic review of the literature. Neurourology and Urodynamics, 2019, 38, 2083-2092.	1.5	19
307	Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review. Clinical Therapeutics, 2019, 41, 1576-1588.	2.5	33
308	Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care. Advances in Therapy, 2019, 36, 3110-3122.	2.9	13
309	A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1125-1132.	0.9	2
310	<p></p>Evaluation of real-world persistence of propiverine and tropsium chloride in treatment of overactive bladder in Germany</p>. Research and Reports in Urology, 2019, Volume 11, 9-13.	1.0	2

#	ARTICLE	IF	CITATIONS
311	Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. <i>BMJ Open</i> , 2019, 9, e027049.	1.9	91
312	Using a checklist to increase the effectiveness of behavioral therapy for overactive bladder: A prospective randomized controlled trial. <i>Neurourology and Urodynamics</i> , 2019, 38, 1152-1159.	1.5	4
313	Adherence in Hypertension. <i>Circulation Research</i> , 2019, 124, 1124-1140.	4.5	401
314	Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000761.	2.8	32
316	A Retrospective Case Series of High-Frequency Spinal Cord Stimulation (HF10-SCS) in Neurogenic Bladder Incontinence. <i>Operative Neurosurgery</i> , 2019, 17, 14-20.	0.8	12
317	Comparing patients' prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid. <i>Journal of Clinical Lipidology</i> , 2019, 13, 170-175.	1.5	1
318	Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 1419-1424.	3.4	27
319	The impact of financial strain on medication non-adherence: Influence of psychiatric medication use. <i>Psychiatry Research</i> , 2019, 271, 389-395.	3.3	7
320	Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 495-503.	3.3	48
321	Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: interim (1-year) report from a Japanese post-marketing surveillance study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 14-23.	1.3	12
322	Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1035-1041.	0.9	14
323	Patient navigation for overactive bladder improves access to care. <i>International Urogynecology Journal</i> , 2020, 31, 1007-1012.	1.4	9
324	The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review. <i>Journal of Orthopaedic Translation</i> , 2020, 22, 7-13.	3.9	25
325	Study protocol: CareAvenue program to improve unmet social risk factors and diabetes outcomes- A randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2020, 89, 105933.	1.8	7
326	Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 103-110.	3.3	7
327	24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients. <i>Drugs</i> , 2020, 80, 167-179.	10.9	63
328	Prevalence and Impact of Having Multiple Barriers to Medication Adherence in Nonadherent Patients With Poorly Controlled Cardiometabolic Disease. <i>American Journal of Cardiology</i> , 2020, 125, 376-382.	1.6	16
329	Reporting of adverse drug events in the Veterans Health Administration for patients whose treatment with empagliflozin or apixaban was discontinued. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 22-32.	1.0	3

#	ARTICLE	IF	CITATIONS
330	Patient Perspectives on Short-Course Pharmacotherapy: Barriers and Facilitators to Medication Adherence. <i>Journal of Patient Experience</i> , 2020, 7, 726-733.	0.9	1
331	Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 573238.	3.5	11
332	Comparing two health literacy measurements used for assessing older adults' medication adherence. <i>Journal of Clinical Nursing</i> , 2020, 29, 4313-4320.	3.0	3
333	Overactive bladder medication: Persistence, drug switching, and reinitiation. <i>Neurourology and Urodynamics</i> , 2020, 39, 2527-2534.	1.5	18
334	Statistical considerations for medication adherence research. <i>Current Medical Research and Opinion</i> , 2020, 36, 1549-1557.	1.9	9
335	Pitfalls of medication adherence approximation through EHR and pharmacy records: Definitions, data and computation. <i>International Journal of Medical Informatics</i> , 2020, 136, 104092.	3.3	22
336	Quality of life and treatment persistence evaluation in Spanish patients treated with mirabegron. Results of the BELIEVE study. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 224-232.	0.2	0
337	<p><p>Decreasing Avoidable Vision Loss: Identifying Antecedents of Adherence</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3735-3739.	1.8	2
338	A retrospective analysis comparing persistence and adherence to treatment with free vs fixed dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain. <i>International Journal of Clinical Practice</i> , 2020, 74, 1280-1290.	1.7	4
339	Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma. <i>Journal of Medical Economics</i> , 2020, 23, 1293-1301.	2.1	1
340	Distribution of 14C-Latanoprost Following a Single Intracameral Administration Versus Repeated Topical Administration. <i>Ophthalmology and Therapy</i> , 2020, 9, 929-940.	2.3	3
341	Sacral neuromodulation system for treating refractory overactive bladder. <i>British Journal of Nursing</i> , 2020, 29, S30-S37.	0.7	4
342	Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1378-1386.	1.5	8
343	Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat. <i>Ophthalmology and Therapy</i> , 2020, 9, 1-8.	2.3	3
344	Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3742.	2.6	7
345	Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). <i>Ophthalmology</i> , 2020, 127, 1627-1641.	5.2	62
346	Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016. <i>Journal of Clinical Lipidology</i> , 2020, 14, 305-314.	1.5	6
347	Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 282.	1.7	10

#	ARTICLE	IF	CITATIONS
348	Self-Administration of Medication in Hospital: A Literature Review. <i>Nursing Science Quarterly</i> , 2020, 33, 249-257.	0.8	7
349	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. <i>American Heart Journal</i> , 2020, 228, 36-43.	2.7	11
350	A computer-guided quality improvement tool for primary health care: cost-effectiveness analysis based on TORPEDO trial data. <i>Medical Journal of Australia</i> , 2020, 213, 73-78.	1.7	7
351	Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. <i>Toxins</i> , 2020, 12, 128.	3.4	26
352	Evolving Guidelines for Intracameral Injection. <i>Journal of Glaucoma</i> , 2020, 29, S1-S7.	1.6	12
353	Prevalence of Universal Medication Schedule prescribing and links to adherence. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 196-205.	1.0	5
354	The Societal Value of Broader Access to Antiobesity Medications. <i>Obesity</i> , 2020, 28, 429-436.	3.0	13
355	Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes. <i>JAMA Network Open</i> , 2020, 3, e1919645.	5.9	8
356	Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System. <i>Advances in Therapy</i> , 2020, 37, 2344-2355.	2.9	5
357	Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. <i>Neurourology and Urodynamics</i> , 2020, 39, 1108-1114.	1.5	12
358	Factors Affecting Preventive Treatment Outcomes for Patients With Newly Diagnosed Chronic Migraine and Their Compliance With Treatment Recommendations in Chongqing Province, China: An Open-Label Prospective Study With Retrospective Baseline. <i>Frontiers in Neurology</i> , 2020, 11, 227.	2.4	6
359	A behavioral economics-based telehealth intervention to improve aspirin adherence following hospitalization for acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 513-517.	1.9	15
360	Matrix Metalloproteinases and Glaucoma Treatment. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 208-228.	1.4	70
361	Measuring and reporting treatment adherence: What can we learn by comparing two respiratory conditions?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 825-836.	2.4	10
362	Improving medication adherence in patients with lupus nephritis. <i>Kidney International</i> , 2021, 99, 285-287.	5.2	9
363	Adherence management in transplantation. , 2021, , 409-448.		3
364	Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study. <i>BMC Ophthalmology</i> , 2021, 21, 52.	1.4	9
365	Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy. <i>Inquiry (United States)</i> , 2021, 58, 004695802199051.	0.9	3

#	ARTICLE	IF	CITATIONS
366	Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 931-938.	1.8	6
367	Comparing the Efficacies of Bisphosphonates™ Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. <i>Current Molecular Medicine</i> , 2022, 22, 274-284.	1.3	2
368	Effect of a Patient Support Program for Idiopathic Pulmonary Fibrosis Patients on Medication Persistence: A Retrospective Database Analysis. <i>Advances in Therapy</i> , 2021, 38, 3888-3899.	2.9	6
369	Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the <scp>PERSPECTIVE</scp> registry study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 425-434.	1.3	16
370	What Happens after Hospital Discharge? Deficiencies in Medication Management Encountered by Geriatric Patients with Polypharmacy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7031.	2.6	8
371	Improving Adherence to Topical Medication in Patients with Glaucoma. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1477-1489.	1.8	21
372	Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity. <i>JAMA Network Open</i> , 2021, 4, e2116595.	5.9	13
373	Sociodemographic Determinants of Nonadherence to Depression and Anxiety Medication among Individuals Experiencing Homelessness. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7958.	2.6	4
374	Mirabegron has longer treatment persistence than antimuscarinics: A real-world data from a Korean national cohort database. <i>Neurourology and Urodynamics</i> , 2021, 40, 1972-1980.	1.5	4
375	Anticholinergic drugs and dementia: time for transparency in the face of uncertainty. <i>The Cochrane Library</i> , 2021, 2021, ED000154.	2.8	4
376	Adherence With Glaucoma Medications: Barriers to Success and Prospects for Improvement. <i>Current Ophthalmology Reports</i> , 2021, 9, 184-189.	1.2	0
377	Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3350.	4.0	15
378	Patient Adherence: Challenges, Myths, and Realities. , 2019, , 381-400.		2
379	Advancing the Science and Practice of Medication Adherence. <i>Journal of General Internal Medicine</i> , 2018, 33, 216-222.	2.6	57
380	Spinal cord stimulation for the restoration of bladder function after spinal cord injury. <i>Healthcare Technology Letters</i> , 2020, 7, 87-92.	3.3	13
381	Do trial-and-error practices and the use of the internet influence how medicines are used?. <i>Australian Journal of Primary Health</i> , 2014, 20, 228.	0.9	1
382	Electronic Health Records As a Platform for Audiological Research: Data Validity, Patient Characteristics, and Hearing-Aid Use Persistence Among 731,213 U.S. Veterans. <i>Ear and Hearing</i> , 2021, 42, 927-940.	2.1	11
383	Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function. <i>JCI Insight</i> , 2019, 4, .	5.0	16

#	ARTICLE	IF	CITATIONS
384	Ensuring optimal adherence to BCR-ABL1 tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Community Oncology</i> , 2013, 10, 138-146.	0.2	2
385	Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data. <i>PLoS ONE</i> , 2017, 12, e0174426.	2.5	64
386	Leuprorelin and Triptorelin in the treatment of Prostate Cancer: Medication adherence, Persistence and Economic Evaluation in Five Years of Analysis. <i>International Journal of Pharmaceutical Sciences Research</i> , 2014, 1, .	0.3	3
387	Systematic Review of Migraine Prophylaxis Adherence and Persistence. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 22-33.	2.2	229
388	REDUCED OUT-OF-POCKET COSTS AND MEDICATION ADHERENCE – A POPULATION-BASED STUDY. <i>Canadian Journal of Clinical Pharmacology</i> , 2018, 25, e1-e17.	1.1	3
389	Twelve-Month Prospective Randomized Study of Pharmacists Utilizing Point-Of-Care Testing for Metabolic Syndrome and Related Conditions in Subjects Prescribed Antipsychotics. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.6	10
390	Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical setting. <i>Urology Annals</i> , 2019, 11, 149.	0.6	2
391	Cross-cultural Adaptation and Validation of Beliefs about Medicines Questionnaire on Asthma and Chronic Obstructive Pulmonary Disease Patients. <i>Turkish Thoracic Journal</i> , 2018, 19, 36-40.	0.6	9
392	Social Risk Factors for Medication Nonadherence: Findings from the CARDIA Study. <i>American Journal of Health Behavior</i> , 2020, 44, 232-243.	1.4	22
393	The Effect of a Novel Proactive First Day Prescription Counseling Program on Adherence to Select Cardiovascular Medications. <i>Innovations in Pharmacy</i> , 2011, 2, .	0.6	0
394	A milestone, and cost effectiveness of preventive drugs. <i>Journal of the Ceylon College of Physicians</i> , 2011, 41, 39.	0.0	0
396	Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus. <i>Pharmacology & Pharmacy</i> , 2014, 05, 332-339.	0.7	0
397	Using Retrospective Databases to Study Adherence. , 2016, , 39-52.		0
398	Overactive Bladder: Changing Paradigms in Current Guidelines and Pharmacotherapy. <i>Annals of SBV</i> , 2017, 6, 15-20.	0.1	0
399	Individualizing Drug Therapy. , 2019, , 291-314.		0
400	Post-transplant Psychosocial and Mental Health Care of the Renal Recipient. , 2019, , 119-136.		2
402	Resultados de la subpoblación española del estudio BELIEVE. Evaluación de la calidad de vida y persistencia al tratamiento de pacientes tratados con mirabegron. <i>Actas Urológicas Españolas</i> , 2020, 44, 224-232.	0.7	0
403	Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2). <i>Drugs</i> , 2021, 81, 2017-2033.	10.9	25

#	ARTICLE	IF	CITATIONS
404	Botulinum Toxin Therapy for Voiding Dysfunction. , 2020, , 255-282.		0
405	Management of erectile dysfunction following robot-assisted radical prostatectomy: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 543-554.	3.9	11
406	Safety and Efficacy of NOACs and Warfarin in Singapore: Are They Really Equivalent?. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 834-835.	0.4	0
407	Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes. <i>P and T</i> , 2012, 37, 464-70.	0.9	3
408	Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes. <i>American Health and Drug Benefits</i> , 2013, 6, 382-92.	0.5	33
409	Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy. <i>American Health and Drug Benefits</i> , 2010, 3, 340-9.	0.5	1
410	Value-Based Benefit Design to Improve Medication Adherence for Employees with Anxiety or Depression. <i>American Health and Drug Benefits</i> , 2015, 8, 263-71.	0.5	3
411	AMCP Nexus 2017 Highlights. <i>American Health and Drug Benefits</i> , 2017, 10, 465-467.	0.5	0
412	Identifying temporal patterns of adherence to antidepressants, bisphosphonates and statins, and associated patient factors. <i>SSM - Population Health</i> , 2022, 17, 100973.	2.7	1
413	Exploring patient experiences coping with using multiple medications: a qualitative interview study. <i>BMJ Open</i> , 2021, 11, e046860.	1.9	3
414	BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER'S DISEASE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2016, 3, 1-13.	2.7	3
415	An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. <i>Eye</i> , 2022, 36, 1154-1167.	2.1	28
416	Use of Statins in Kidney Transplant Recipients in Norway. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1370.	2.6	0
417	Patterns and Predictors of Medication Change after Discharge from Hospital: An Observational Study in Older Adults with Neurological Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 563.	2.4	1
418	Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. <i>Expert Review of Medical Devices</i> , 2022, 19, 161-187.	2.8	7
419	A machine-learning assisted review of the use of habit formation in medication adherence interventions for long-term conditions. <i>Health Psychology Review</i> , 2024, 18, 1-23.	8.6	6
420	Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 165.e1-165.e9.	1.2	6
421	Integrating Pharmacy and Registry Data Strengthens Clinical Assessments of Patient Adherence. <i>Frontiers in Pharmacology</i> , 2022, 13, 869162.	3.5	1

#	ARTICLE	IF	CITATIONS
422	Neurogenic bladder " concepts and treatment recommendations. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 220-243.	1.5	11
423	Optimal Measures for Primary Care Physician Encounters after Stroke and Association with Survival: A Data Linkage Study. Neuroepidemiology, 2022, 56, 90-96.	2.3	3
424	Reviving Cav1.2 as an attractive drug target to treat bladder dysfunction. FASEB Journal, 2022, 36, e22118.	0.5	2
425	Closed-loop sacral neuromodulation for bladder function using dorsal root ganglia sensory feedback in an anesthetized feline model. Medical and Biological Engineering and Computing, 2022, 60, 1527-1540.	2.8	5
426	Applying Mixture Cure Survival Modeling to Medication Persistence Analysis. Pharmacoepidemiology and Drug Safety, 2022, , .	1.9	0
427	Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence. British Journal of Clinical Pharmacology, 2023, 89, 1992-1995.	2.4	2
428	Utilization rate and long-term persistence of combination pharmacotherapy with β_3 agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real-world setting. Neurourology and Urodynamics, 2022, , .	1.5	0
430	Combination and Novel Pharmacologic Agents for OAB. Current Urology Reports, 2022, , 1.	2.2	0
431	Investigating the needs and concerns of older adults with multimorbidity and their healthcare professionals for conceivable digital psychotherapeutic interventions. Digital Health, 2022, 8, 205520762210890.	1.8	1
432	Associations between personality traits and adherence to treatment in patients with primary open-angle glaucoma in an African population. Australasian journal of optometry, The, 2023, 106, 509-515.	1.3	2
433	Single Administration of Intracameral Bimatoprost Implant 10 μ g in Patients with Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology and Therapy, 2022, 11, 1517-1537.	2.3	9
434	Effects of β_3 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder. In Vivo, 2022, 36, 1847-1853.	1.3	0
435	Understanding medication use behaviors and perspectives in an older cardiovascular patient population: Opportunities for patient-centered deprescribing. American Heart Journal Plus, 2022, 17, 100164.	0.6	0
436	Associations among Physician-Patient Communication, Patient Satisfaction, and Clinical Effectiveness of Overactive Bladder Medication: A Survey of Patients with Overactive Bladder. Journal of Clinical Medicine, 2022, 11, 4087.	2.4	4
437	Busting for change: a care pathway for overactive bladder. Trends in Urology & Men's Health, 2022, 13, 17-21.	0.4	1
438	Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer. JAMA Network Open, 2022, 5, e2225485.	5.9	12
439	Alendronato de s \ddot{a} dio e vitamina D na osteoporose p \ddot{a} s-menopausa. Scientia Medica, 2022, 32, e42267.	0.3	0
440	A systematic review of primary care-focused, self-reported medication adherence tools. Journal of the American Pharmacists Association: JAPhA, 2023, 63, 477-490.e1.	1.5	3

#	ARTICLE	IF	CITATIONS
441	Behaviour Change to Promote Diabetes Outcomes: Getting More From What We Have Through Dissemination and Scalability. Canadian Journal of Diabetes, 2022, , .	0.8	1
442	Migraine treatment in patients with poor compliance. Neurologie Pro Praxi, 2022, 23, 324-329.	0.1	0
443	Adherence patterns in naïve and prevalent use of infliximab and its biosimilar. BMC Rheumatology, 2022, 6, .	1.6	0
444	Patterns of statin adherence in primary cardiovascular disease prevention during the pandemic. Frontiers in Pharmacology, 0, 13, .	3.5	3
446	Medication nonadherence: health impact, prevalence, correlates and interventions. Psychology and Health, 2023, 38, 726-765.	2.2	5
447	Adherence to lipid-lowering therapy and reaching treatment goals in youth seen in a preventive cardiology clinic. Research in Social and Administrative Pharmacy, 2022, , .	3.0	1
448	Persistence to Medications for Benign Prostatic Hyperplasia/Benign Prostatic Obstruction-Associated Lower Urinary Tract Symptoms in the ASL TO4 Regione Piemonte (Italy). Healthcare (Switzerland), 2022, 10, 2567.	2.0	2
449	A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan. Rheumatology and Therapy, 2023, 10, 615-634.	2.3	0
450	Proposed Mechanism of Long-Term Intraocular Pressure Lowering With the Bimatoprost Implant. , 2023, 64, 15.		5
451	Emerging glaucoma treatments: are we seeing an improvement in adherence?. Expert Review of Ophthalmology, 2023, 18, 101-111.	0.6	1
452	Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant. Journal of Ocular Pharmacology and Therapeutics, 2023, 39, 398-403.	1.4	2
453	Persistence of overactive bladder pharmacological treatment in women as reflected from large-scale real-world data of prescription claims: A retrospective cohort study. Neurourology and Urodynamics, 2023, 42, 1491-1498.	1.5	0
454	Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Clinical Rheumatology, 0, , .	2.2	0
456	Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA. BMJ Open, 2023, 13, e075840.	1.9	0
457	Adherence and persistence of HIV pre-exposure prophylaxis use in the United States. Pharmacoepidemiology and Drug Safety, 2024, 33, .	1.9	0
458	Multi-omic approaches provide insights into the molecular mechanisms of Sojæ semen germinatum water extract against overactive bladder. Food Research International, 2024, 175, 113746.	6.2	0
459	Personality Traits Associated with Treatment Choice with an Explicit Statistical Prediction After an Explanation in a Negative Context: A Study in Patients with Glaucoma. Clinical Ophthalmology, 0, Volume 17, 3685-3691.	1.8	1
460	Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States. Clinical Ophthalmology, 0, Volume 18, 187-199.	1.8	0